Summary
Abuse of prescription opioids continues to be a serious public health concern, with as many as 12.5 million individuals aged 12 or older reporting nonmedical use of prescription pain relievers in 2015. Oxycodone ARIR is the first abuse-deterrent formulation of an IR opioid approved by the Food and Drug Administration and was developed to have similar relative bioavailability to IR oxycodone. Patients can be converted from IR oxycodone to the same dose and dosing regimen of Oxycodone ARIR. It has been demonstrated that when crushed and taken intranasally, Oxycodone ARIR has a 47% and a 23% reduction in mean maximum drug liking compared with crushed intranasal IR oxycodone and intact oral Oxycodone ARIR, respectively.
Register to download
Pharmacokinetic Characteristics of Intranasal Administration of Oxycodone ARIR
You may also be interested in:
Poster
Marijuana Effect on Differentiating an Opioid from Placebo During the Discrimination Phase of a Human Abuse Potential Study
Subjects of human abuse potential (HAP) studies must be able to detect liking with the investigational drug. However, many subjects recruited for HAP…
White Paper
PRA Insights Report: Alzheimer's Disease Research
This PRA Insights report focusing on Alzheimer’s disease research was compiled from survey data gathered at the 2017 Alzheimer’s Association…
Blog
Ask the Experts: What Do We Need to Know About ALZ and other Brain-Related Illnesses?
Many people have heard of brain-related illnesses such as Alzheimer’s (ALZ). In honor of Brain Awareness Month, we shed some light on ALZ and other…